Hoth Therapeutics Alzheimer's Treatment Shows Improvement In Cognitive Function, Anxiety

Hoth Therapeutics Inc HOTH announced that HT-ALZ, a therapeutic in development for Alzheimer's Disease (AD), achieved positive preclinical endpoints in a study.

Subjects treated with HT-ALZ show improvement on several cognitive function tests, including spatial learning and memory, sensorimotor gating, and contextual associative memory. HT-ALZ showed positive benefits in reducing anxiety-like behavior in mice.

The study was conducted at Washington University, St. Louis.

Previously, Hoth reported study results focused on investigating the effect of orally administered HT-ALZ to reduce the concentration of Aβ in the brain interstitial fluid using an established Alzheimer's Disease mouse model (aged APP/PS1+/- mice). 

The initial data from those studies showed a significant decrease in Aβ in both male and female APP/PS1+/- mice after acute treatment with HT-ALZ, compared to placebo-treated animals and baseline Aβ levels.

Price Action: HOTH shares are up 6.20% at $2.39 on the last check Wednesday.